candesartan has been researched along with Coronary Artery Disease in 23 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Coronary Artery Disease: Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this post hoc subgroup analysis was to compare the incidence of major adverse cardiovascular events (MACE) of patients treated with candesartan and amlodipine with that of those with candesartan and non-amlodipine CCBs in hypertensive patients with coronary artery disease (CAD)." | 9.17 | Efficacy of the combination of amlodipine and candesartan in hypertensive patients with coronary artery disease: a subanalysis of the HIJ-CREATE study. ( Hagiwara, N; Haruta, S; Kawada-Watanabe, E; Koyanagi, R; Ogawa, H; Takagi, A; Yamaguchi, J, 2013) |
| "The aim of the present study was to clarify the influence of candesartan-based therapy on subsequent carcinogenesis and cancer death in patients with coronary artery disease with hypertension in a substudy of a multicenter, prospective, randomized, controlled trial." | 9.16 | Candesartan-based therapy and risk of cancer in patients with systemic hypertension (Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] substudy). ( Hagiwara, N; Koyanagi, R; Ogawa, H; Oka, T; Sugiura, R, 2012) |
| "Angiographically documented CAD patients with hypertension were randomly assigned to receive either candesartan-based (n= 1024) or non-ARB-based pharmacotherapy including angiotensin-converting enzyme-inhibitors (n = 1025)." | 9.14 | Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in ( Hagiwara, N; Haze, K; Honda, T; Hosoda, S; Kasanuki, H; Nagashima, M; Ogawa, H; Origasa, H; Sumiyoshi, T; Urashima, M; Yamaguchi, J, 2009) |
| "Candesartan has been reported to reduce cardiovascular events when therapy was started 6 months after PCI with bare-metal stents in patients who survived restenosis." | 6.82 | Impact of candesartan on cardiovascular events after drug-eluting stent implantation in patients with coronary artery disease: The 4C trial. ( Hokimoto, S; Kikuta, K; Kimura, K; Koide, S; Matsui, K; Matsumura, T; Nakao, K; Ogawa, H; Oka, H; Oshima, S; Sakamoto, T; Shimomura, H; Tsujita, K; Yamamoto, N, 2016) |
| "The purpose of this post hoc subgroup analysis was to compare the incidence of major adverse cardiovascular events (MACE) of patients treated with candesartan and amlodipine with that of those with candesartan and non-amlodipine CCBs in hypertensive patients with coronary artery disease (CAD)." | 5.17 | Efficacy of the combination of amlodipine and candesartan in hypertensive patients with coronary artery disease: a subanalysis of the HIJ-CREATE study. ( Hagiwara, N; Haruta, S; Kawada-Watanabe, E; Koyanagi, R; Ogawa, H; Takagi, A; Yamaguchi, J, 2013) |
| "The aim of the present study was to clarify the influence of candesartan-based therapy on subsequent carcinogenesis and cancer death in patients with coronary artery disease with hypertension in a substudy of a multicenter, prospective, randomized, controlled trial." | 5.16 | Candesartan-based therapy and risk of cancer in patients with systemic hypertension (Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] substudy). ( Hagiwara, N; Koyanagi, R; Ogawa, H; Oka, T; Sugiura, R, 2012) |
| "One hundred and five patients eligible for coronary artery bypass graft surgery (65-85 years old, all suffering from hypertension and coronary artery disease, with stable kidney function) were randomized to candesartan (8 mg od) or placebo for between 8 and 11 days prior to surgery." | 5.14 | ARTA: AT1-receptor blocker therapy in patients undergoing coronary artery bypass grafting. ( Erdmann, E; Flesch, M; Geissler, HJ; Kessler, G; Knipp, S; Massoudy, P; Philipp, T; Wilhelm, H, 2009) |
| "Angiographically documented CAD patients with hypertension were randomly assigned to receive either candesartan-based (n= 1024) or non-ARB-based pharmacotherapy including angiotensin-converting enzyme-inhibitors (n = 1025)." | 5.14 | Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in ( Hagiwara, N; Haze, K; Honda, T; Hosoda, S; Kasanuki, H; Nagashima, M; Ogawa, H; Origasa, H; Sumiyoshi, T; Urashima, M; Yamaguchi, J, 2009) |
| "The aim of this study was to assess the effects of angiotensin receptor blocker (ARB)-based therapy on cardiovascular events in high-risk hypertensive patients with coronary artery disease (CAD) and impaired renal function in post hoc analysis of HIJ-CREATE (Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease)." | 5.14 | Angiotensin receptor blocker-based therapy and cardiovascular events in hypertensive patients with coronary artery disease and impaired renal function. ( Hagiwara, N; Haze, K; Honda, T; Kasanuki, H; Kawana, M; Ogawa, H; Origasa, H; Shiga, T; Sumiyoshi, T; Takagi, A, 2010) |
| "Candesartan has been reported to reduce cardiovascular events when therapy was started 6 months after PCI with bare-metal stents in patients who survived restenosis." | 2.82 | Impact of candesartan on cardiovascular events after drug-eluting stent implantation in patients with coronary artery disease: The 4C trial. ( Hokimoto, S; Kikuta, K; Kimura, K; Koide, S; Matsui, K; Matsumura, T; Nakao, K; Ogawa, H; Oka, H; Oshima, S; Sakamoto, T; Shimomura, H; Tsujita, K; Yamamoto, N, 2016) |
| " Furthermore, because of the notorious subtarget dosing of such agents in clinical practice, we explored the influence of a modest dosing of an angiotensin-converting enzyme inhibitor, angiotensin II type 1 receptor blockers, and the combination on common biologic markers of coronary atherosclerotic disease." | 2.72 | Lack of effect on coronary atherosclerotic disease biomarkers with modest dosing of an angiotensin-converting enzyme inhibitor, angiotensin II type-1 receptor blocker, and the combination. ( Cox, CD; Meyerrose, GE; Peek, MC; Seifert, CF; Simoni, JS; Tsikouris, JP, 2006) |
| " Further research is necessary to determine which AT1RBs and which dosing regimens are optimal." | 2.41 | Emerging role of angiotensin II type 1 receptor blockers for the treatment of endothelial dysfunction and vascular inflammation. ( Mancini, GB, 2002) |
| "Gross proteinuria was largely unaffected by (AT1R) blockade and renal function further declined necessitating, initiation of hemodialysis." | 1.36 | Gross proteinuria and subacute renal failure after coronary angiography - a case report of cholesterol crystal embolization. ( Biesenbach, P; Gremmel, T; Hörl, WH; Kain, R; Säemann, MD, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (39.13) | 29.6817 |
| 2010's | 12 (52.17) | 24.3611 |
| 2020's | 2 (8.70) | 2.80 |
| Authors | Studies |
|---|---|
| Kikuchi, N | 2 |
| Ogawa, H | 9 |
| Kawada-Watanabe, E | 2 |
| Arashi, H | 1 |
| Jujo, K | 2 |
| Sekiguchi, H | 1 |
| Yamaguchi, J | 5 |
| Hagiwara, N | 8 |
| Chen, YJ | 1 |
| Chiang, CE | 1 |
| Cheng, HM | 1 |
| Lee, SR | 1 |
| Chae, IH | 1 |
| Kim, HL | 1 |
| Kang, DY | 1 |
| Kim, SH | 1 |
| Kim, HS | 1 |
| Koyanagi, R | 3 |
| Haruta, S | 1 |
| Takagi, A | 3 |
| Sakamoto, T | 1 |
| Nakao, K | 2 |
| Hokimoto, S | 1 |
| Tsujita, K | 1 |
| Koide, S | 1 |
| Yamamoto, N | 1 |
| Shimomura, H | 1 |
| Matsumura, T | 1 |
| Oshima, S | 1 |
| Kikuta, K | 1 |
| Oka, H | 1 |
| Kimura, K | 1 |
| Matsui, K | 1 |
| Flesch, M | 1 |
| Knipp, S | 1 |
| Kessler, G | 1 |
| Geissler, HJ | 1 |
| Massoudy, P | 1 |
| Wilhelm, H | 1 |
| Philipp, T | 1 |
| Erdmann, E | 1 |
| Kasanuki, H | 4 |
| Hosoda, S | 1 |
| Sumiyoshi, T | 2 |
| Honda, T | 2 |
| Haze, K | 2 |
| Nagashima, M | 2 |
| Origasa, H | 2 |
| Urashima, M | 1 |
| Perrone-Filardi, P | 1 |
| Corrado, L | 1 |
| Brevetti, G | 1 |
| Silvestro, A | 1 |
| Dellegrottaglie, S | 1 |
| Cafiero, M | 1 |
| Caiazzo, G | 1 |
| Petretta, A | 1 |
| Maglione, A | 1 |
| Monda, C | 1 |
| Guerra, G | 1 |
| Marzano, A | 1 |
| Cesarano, P | 1 |
| Gargiulo, P | 1 |
| Chiariello, M | 1 |
| Shiga, T | 1 |
| Kawana, M | 1 |
| Biesenbach, P | 1 |
| Gremmel, T | 1 |
| Hörl, WH | 1 |
| Kain, R | 1 |
| Säemann, MD | 1 |
| Mori, F | 1 |
| Yagi, M | 1 |
| Suzuki, T | 1 |
| Nozawa, T | 1 |
| Fujii, N | 1 |
| Sobajima, M | 1 |
| Ohori, T | 1 |
| Shida, T | 1 |
| Matsuki, A | 1 |
| Kameyama, T | 1 |
| Inoue, H | 1 |
| Ueshima, K | 1 |
| Oba, K | 1 |
| Yasuno, S | 1 |
| Fujimoto, A | 1 |
| Tanaka, S | 1 |
| Ogihara, T | 1 |
| Saruta, T | 1 |
| Sugiura, R | 1 |
| Oka, T | 1 |
| Iino, K | 1 |
| Watanabe, H | 1 |
| Iino, T | 1 |
| Katsuta, M | 1 |
| Koyama, T | 1 |
| Kosaka, T | 1 |
| Terui, G | 1 |
| Ito, H | 1 |
| Rueckschloss, U | 1 |
| Quinn, MT | 1 |
| Holtz, J | 1 |
| Morawietz, H | 1 |
| Mancini, GB | 1 |
| Hornig, B | 1 |
| Kohler, C | 1 |
| Schlink, D | 1 |
| Tatge, H | 1 |
| Drexler, H | 1 |
| Füessl, HS | 1 |
| Tsikouris, JP | 1 |
| Cox, CD | 1 |
| Simoni, JS | 1 |
| Seifert, CF | 1 |
| Peek, MC | 1 |
| Meyerrose, GE | 1 |
| van de Wal, RM | 1 |
| van der Harst, P | 1 |
| Wagenaar, LJ | 1 |
| Wassmann, S | 1 |
| Morshuis, WJ | 1 |
| Nickenig, G | 1 |
| Buikema, H | 1 |
| Plokker, HW | 1 |
| van Veldhuisen, DJ | 1 |
| van Gilst, WH | 1 |
| Voors, AA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Candesartan Cilexetil on Cardiovascular Events in Japanese Patients With Hypertension After Sirolimus- or Paclitaxel-Eluting Stents Implantation[NCT00139386] | Phase 4 | 1,119 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for candesartan and Coronary Artery Disease
| Article | Year |
|---|---|
Emerging role of angiotensin II type 1 receptor blockers for the treatment of endothelial dysfunction and vascular inflammation.
Topics: Acrylates; Aged; Antihypertensive Agents; Benzimidazoles; Biomarkers; Biphenyl Compounds; Coronary A | 2002 |
14 trials available for candesartan and Coronary Artery Disease
| Article | Year |
|---|---|
Predictors of candesartan's effect on vascular reactivity in patients with coronary artery disease.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Brachial Artery; | 2017 |
Efficacy of the combination of amlodipine and candesartan in hypertensive patients with coronary artery disease: a subanalysis of the HIJ-CREATE study.
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Calcium Chan | 2013 |
Impact of candesartan on cardiovascular events after drug-eluting stent implantation in patients with coronary artery disease: The 4C trial.
Topics: Aged; Angina, Unstable; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cardiovascular | 2016 |
Impact of left ventricular ejection function on blood pressure-lowering therapy in hypertensive patients with coronary artery disease.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Coronary Artery D | 2016 |
ARTA: AT1-receptor blocker therapy in patients undergoing coronary artery bypass grafting.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds | 2009 |
Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angiotensin II Type 1 Receptor Blockers; Benzimidaz | 2009 |
Effects of AT1 receptor antagonism with candesartan on endothelial function in patients with hypertension and coronary artery disease.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl | 2009 |
Angiotensin receptor blocker-based therapy and cardiovascular events in hypertensive patients with coronary artery disease and impaired renal function.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2010 |
Effect of amlodipine + candesartan on cardiovascular events in hypertensive patients with coronary artery disease (from The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] Study).
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angina, Unstable; Angiotensin II Type 1 Receptor Blocker | 2010 |
Candesartan-based therapy and risk of cancer in patients with systemic hypertension (Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] substudy).
Topics: Age Factors; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Coronary Artery Dise | 2012 |
Candesartan improves impaired endothelial function in the human coronary artery.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Flow Veloci | 2012 |
[The Heart Institute of Japan--candesartan randomized trial for evaluation in CAD (HUJ-CREATE)].
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Coronary Artery D | 2011 |
AT1-receptor antagonism improves endothelial function in coronary artery disease by a bradykinin/B2-receptor-dependent mechanism.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazol | 2003 |
Lack of effect on coronary atherosclerotic disease biomarkers with modest dosing of an angiotensin-converting enzyme inhibitor, angiotensin II type-1 receptor blocker, and the combination.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2006 |
8 other studies available for candesartan and Coronary Artery Disease
| Article | Year |
|---|---|
Impact of age on clinical outcomes of antihypertensive therapy in patients with hypertension and coronary artery disease: A sub-analysis of the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease.
Topics: Age Factors; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2020 |
Rethinking of the hypertension management in the elderly with comorbidity: Should we forget the age in treating elderly hypertensives?
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Comorbidity; Coronary Artery Dise | 2020 |
Gross proteinuria and subacute renal failure after coronary angiography - a case report of cholesterol crystal embolization.
Topics: Acute Kidney Injury; Angiotensin II Type 1 Receptor Blockers; Austria; Benzimidazoles; Biopsy; Biphe | 2010 |
Combination therapy of candesartan with statin inhibits progression of atherosclerosis more than statin alone in patients with coronary artery disease.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anticholesteremic Agents; Atherosclerosis; Atorvastat | 2011 |
Influence of coronary risk factors on coronary events in Japanese high-risk hypertensive patients. - Primary and secondary prevention of ischemic heart disease in a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) tria
Topics: Aged; Amlodipine; Antihypertensive Agents; Asian People; Benzimidazoles; Biphenyl Compounds; Coronar | 2011 |
Dose-dependent regulation of NAD(P)H oxidase expression by angiotensin II in human endothelial cells: protective effect of angiotensin II type 1 receptor blockade in patients with coronary artery disease.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Cells, Culture | 2002 |
[Acute coronary syndrome you can hear the prognosis].
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Clinical Trials as Topic; Coronary Arte | 2004 |
Angiotensin II type 2 receptor vasoactivity in internal mammary arteries of patients with coronary artery disease.
Topics: Acetylcholine; Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin II; Angiote | 2007 |